- Home
- PKBK vs AARD Comparison
PKBK vs AARD Comparison
Compare PKBK & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- AARD
- Stock Information
- Founded
- PKBK 1999
- AARD 2017
- Country
- PKBK United States
- AARD United States
- Employees
- PKBK N/A
- AARD N/A
- Industry
- PKBK Major Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- AARD Health Care
- Exchange
- PKBK Nasdaq
- AARD Nasdaq
- Market Cap
- PKBK 256.4M
- AARD 242.9M
- IPO Year
- PKBK N/A
- AARD 2025
- Fundamental
- Price
- PKBK $22.25
- AARD $9.77
- Analyst Decision
- PKBK
- AARD Strong Buy
- Analyst Count
- PKBK 0
- AARD 5
- Target Price
- PKBK N/A
- AARD $32.80
- AVG Volume (30 Days)
- PKBK 27.0K
- AARD 48.9K
- Earning Date
- PKBK 10-17-2025
- AARD 08-13-2025
- Dividend Yield
- PKBK 3.39%
- AARD N/A
- EPS Growth
- PKBK 42.58
- AARD N/A
- EPS
- PKBK 2.56
- AARD N/A
- Revenue
- PKBK $66,879,999.00
- AARD N/A
- Revenue This Year
- PKBK N/A
- AARD N/A
- Revenue Next Year
- PKBK N/A
- AARD N/A
- P/E Ratio
- PKBK $8.29
- AARD N/A
- Revenue Growth
- PKBK 3.52
- AARD N/A
- 52 Week Low
- PKBK $16.94
- AARD $4.88
- 52 Week High
- PKBK $24.29
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- PKBK 62.96
- AARD N/A
- Support Level
- PKBK $21.23
- AARD N/A
- Resistance Level
- PKBK $22.24
- AARD N/A
- Average True Range (ATR)
- PKBK 0.49
- AARD 0.00
- MACD
- PKBK 0.05
- AARD 0.00
- Stochastic Oscillator
- PKBK 98.67
- AARD 0.00
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.